<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391117000295897806874639.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391117000295897806874639.jpeg"/>
Leidi Network, Jianping Lei, April 7
InnoCare Pharma Co., Ltd. (stock code: 688428, abbreviated as InnoCare) recently released its financial report for the period ending December 31, 2025. The report shows that InnoCare's revenue for 2025 is CNY 2.375 billion, an increase of 135.27% compared to CNY 1.009 billion in the same period last year;
Among them, InnoCare's pharmaceutical sales revenue for 2025 is CNY 1.442 billion, an increase of 43.43% compared to CNY 1.006 billion in the same period last year, mainly due to the continuous increase in sales volume of Orelabrutinib and the new sales of Tanshinone Monoclonal Antibody, as well as revenue recognition from licensing agreements achieved this year.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116999058397886755272.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116999058397886755272.jpeg"/>
InnoCare's net profit for 2025 is CNY 642 million, compared to a net loss of CNY 441 million in the same period last year; the net profit after deducting non-recurring items is CNY 553 million, compared to a net loss of CNY 440 million in the same period last year.
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116998458399301788305.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116998458399301788305.jpeg"/>
InnoCare's revenue for the fourth quarter of 2025 is CNY 1.26 billion, with a net profit of CNY 707 million and a net profit of CNY 689 million after deducting non-recurring items.
King Bridge liquidates, possibly cashing out CNY 2 billion
As of December 31, 2025, Hillhouse's HHLR and its concerted parties hold 11.8251%, Sunny View Holdings and the Renbin Zhao (Zhao Renbin, Shi Yigong) family hold 8.2066%, and Sunland BioMed Ltd and the Jisong Cui (Cui Jisong) family hold 7.1976%;
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116997803710737921517.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116997803710737921517.jpeg"/>
As of December 31, 2025, InnoCare's equity structure
China Construction Bank Corporation - Fortune Fund Precision Medicine Flexible Allocation Mixed Securities Investment Fund holds 0.6888%, Chen Xiaofa holds 0.4226%, China Construction Bank Corporation - ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund holds 0.3967%, China Construction Bank Corporation - Huatai-PineBridge Innovative Medicine Theme Mixed Securities Investment Fund holds 0.3302%.
China Merchants Bank Co., Ltd. - Huatai-PineBridge Medical Services Flexible Allocation Mixed Securities Investment Fund holds 0.3269%, Logan Long holds 0.315%.
As of September 30, 2025, Hillhouse's HHLR and its concerted parties hold 11.8251%, Sunny View Holdings and Renbin Zhao (Zhao Renbin, Shi Yigong) family hold 8.2066%, Sunland BioMed Ltd and Jisong Cui (Cui Jisong) family hold 7.1976%, King Bridge Investments Limited and its concerted parties hold 6.9176%, China Construction Bank Corporation - Fortune Fund Precision Medicine Flexible Allocation Mixed Securities Investment Fund holds 0.6888%, Bank of Communications Co., Ltd. - Wanji Industry Preferred Mixed Securities Investment Fund (LOF) holds 0.5667%;
<img src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116996131835618763894.jpeg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260407/6391116996131835618763894.jpeg"/>
As of September 30, 2025, the equity structure of InnoCare Pharma
Bank of China Limited - Ping An Medical Health Mixed Securities Investment Fund holds 0.4889%, China Construction Bank Corporation - ICBC Credit Suisse Frontier Medical Equity Securities Investment Fund holds 0.4533%, China Construction Bank Corporation - Huatai-PineBridge Innovative Medicine Theme Mixed Securities Investment Fund holds 0.3888%.
Comparatively, King Bridge Investments Limited and its concerted parties have exited the top ten shareholders, with a holding ratio below 0.3%, possibly having liquidated their positions.
Currently, InnoCare Pharma's stock price is 29.47 yuan, with a market value of 52 billion yuan. Conservatively estimated, King Bridge has cashed out over 2 billion yuan.
———————————————

688428

516500

159992

InnoCare Pharma Co., Ltd. released its financial report for the period ending December 31, 2025, with revenue of 2.375 billion yuan and a net profit of 642 million yuan, a significant improvement compared to a net loss of 441 million yuan in the same period last year. The increase in drug sales revenue is mainly attributed to the rise in sales of Orelabrutinib and Tanshinone IIA. King Bridge may have fully liquidated its position, cashing out approximately 2 billion yuan

雷帝触网

InnoCare Pharma

ChinaAMC CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Huaan Hang Seng Biotech ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

INNOCARE

InnoCare Pharma annual revenue of 2.4 billion: net profit of 640 million, King Bridge liquidates or cashes out 2 billion